文献速递胸部肿瘤放疗放疗物理与技术

肺癌呼吸控制放疗:最佳应用实践的系统评估

Respiration-controlled radiotherapy in lung cancer: Systematic evaluation of the optimal application practice.
PubMed 文献 · Clin Transl Radiat Oncol · 2023-04-17

本研究前瞻性纳入24例胸部放疗患者,对比自由浅呼吸呼气末门控(FB-EH)与自主深吸气屏气(DIBH)两种呼吸控制技术下的肺和心脏剂量。结果显示上叶肿瘤DIBH在肺和心脏剂量上优于FB-EH,下叶肿瘤两种技术无差异,FB-EH重复性好,推荐用于下叶肿瘤。

要点

  • 上叶肿瘤DIBH较FB-EH降低平均肺剂量(p=0.011)、肺V20(p=0.002)和平均心脏剂量(p=0.016)。
  • 下叶肿瘤FB-EH与DIBH在平均肺剂量(p=0.683)、V20Gy(p=0.33)和平均心脏剂量(p=0.929)上无差异。
  • FB-EH在线控制每分次且重复性好,被推荐为下叶肿瘤的稳健高效技术。

核心结论

  • 肺癌放疗计划取决于DIBH的重复性和呼吸状态对危及器官的优势,上叶肿瘤DIBH较FB-EH有优势,下叶肿瘤两者无差异,FB-EH被推荐为下叶肿瘤的稳健高效技术。

研究设计与样本

  • 前瞻性注册研究,纳入24例接受胸部放疗的患者,在自主深吸气屏气和自由浅呼吸呼气末门控两种呼吸状态下行计划CT。
  • 使用Varian实时位置管理系统(RPM)监测呼吸,在两种计划CT上勾画危及器官、GTV、CTV和PTV,PTV外放为轴向5 mm、头脚方向6-8 mm。
  • 使用相同技术(固定野IMRT或VMAT)在两种呼吸位置生成并比较放疗计划,通过弹性变形检查勾画一致性。

主要发现

  • 下叶肿瘤FB-EH的PTV平均显著小于DIBH的PTV:431.5 vs 477.6 ml(p=0.004)。
  • 上叶肿瘤FB-EH的PTV平均显著小于DIBH的PTV:659.5 vs 686.8 ml(p=0.005)。
  • 上叶肿瘤DIBH的危及器官剂量低于FB-EH:平均肺剂量p=0.011,肺V20 p=0.002,平均心脏剂量p=0.016。
  • 下叶肿瘤FB-EH与DIBH的危及器官剂量无差异:平均肺剂量p=0.683,V20Gy p=0.33,平均心脏剂量p=0.929。
  • FB-EH的放疗设置每分次在线控制,重复性稳健。

关键数值与推荐

  • 上叶肿瘤:DIBH在平均肺剂量(p=0.011)、肺V20(p=0.002)和平均心脏剂量(p=0.016)上优于FB-EH。
  • 下叶肿瘤:FB-EH与DIBH在平均肺剂量(p=0.683)、V20Gy(p=0.33)和平均心脏剂量(p=0.929)上无差异。
  • FB-EH被推荐为下叶肿瘤的非常稳健且高效的技术。

临床怎么用

  • 上叶肿瘤放疗可优先考虑DIBH以降低肺和心脏剂量。
  • 下叶肿瘤放疗可选择FB-EH,因其与DIBH相比肺和心脏暴露无差异且重复性好。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Definitive radiochemotherapy (RCT) for non-small cell lung cancer (NSCLC) in UICC/TNM I-IVA (singular, oligometastatic) is one of the treatment methods with a potentially curative concept. However, tumour respiratory motion during RT requires exact pre-planning. There are various techniques of motion management like creating internal target volume (ITV), gating, inspiration breath-hold and tracking. The primary goal is to cover the PTV with the prescribed dose while at the same time maximizing dose reduction of surrounding normal tissues (organs at risk, OAR). In this study, two standardized online breath-controlled application techniques used alternately in our department are compared with respect to lung and heart dose. MATERIALS AND METHODS: Twenty-four patients who were indicated for thoracic RT received planning CTs in voluntary deep inspiration breath-hold (DIBH) and in free shallow breathing, prospectively gated in expiration (FB-EH). A respiratory gating system by Varian (Real-time Position Management, RPM) was used for monitoring. OAR, GTV, CTV and PTV were contoured on both planning CTs. The PTV margin to the CTV was 5 mm in the axial and 6-8 mm in the cranio-caudal direction. The consistency of the contours was checked by elastic deformation (Varian Eclipse Version 15.5). RT plans were generated and compared in both breathing positions using the same technique, IMRT over fixed irradiation directions or VMAT. The patients were treated in a prospective registry study with the approval of the local ethics committee. RESULTS: The PTV in expiration (FB-EH) was on average significantly smaller than the PTV in inspiration (DIBH): for tumours in the lower lobe (LL) 431.5 vs. 477.6 ml (Wilcoxon test for connected samples; p = 0.004), in the upper lobe (UL) 659.5 vs. 686.8 ml (p = 0.005). The intra-patient comparison of plans in DIBH and FB-EH showed superiority of DIBH for UL-tumours and equality of DIBH and FB-EH for LL-tumours. The dose for OAR in UL-tumours was lower in DIBH than in FB-EH (mean lung dose p = 0.011; lungV20, p = 0.002; mean heart dose p = 0.016). The plans for LL-tumours in FB-EH showed no difference in OAR compared to DIBH (mean lung dose p = 0.683; V20Gy p = 0.33; mean heart dose p = 0.929). The RT setting was controlled online for each fraction and was robustly reproducible in FB-EH. CONCLUSION: RT plans for treating lung tumours implemented depend on the reproducibility of the DIBH and advantages of the respiratory situation with respect to OAR. The primary tumour localization in UL correlates with advantages of RT in DIBH, compared to FB-EH. For LL-tumours there is no difference between RT in FB-EH and RT in DIBH with respect to heart or lung exposure and therefore, reproducibility is the dominant criterion. FB-EH is recommended as a very robust and efficient technique for LL-tumours.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Guberina M, Santiago A, Pöttgen C, et al. Respiration-controlled radiotherapy in lung cancer: Systematic evaluation of the optimal application practice. Clin Transl Radiat Oncol. 2023. PMID: 37138702. doi:10.1016/j.ctro.2023.100628

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。